Sustanon 250: The Definitive Guide

What is Sustanon 250?

Sustanon 250 is a prescription testosterone injection given deep into a muscle. Instead of one form of testosterone, it contains four, each with a different chemical tail (an ester) that makes it dissolve in oil and leave the injection site at a different speed. The body removes the tails to release ordinary testosterone. It is licensed to replace testosterone in men whose deficiency has been confirmed by symptoms and blood tests. [1]

[1], [2]

The "250" is the weight of the four esters together. Because the tails add weight, one ampoule holds 176 mg of testosterone itself. The esters are dissolved in refined peanut (arachis) oil with benzyl alcohol, and the UK product comes as a box of one 1 mL glass ampoule. The labels say only that the four esters have "different durations of action"; no label or study gives the release time of each one inside Sustanon. [1], [2]

Where it is sold (checked September 2026).

[1], [2], [3], [4], [5], [6], [7], [8], [9]

The UK patient leaflet says the injection "should only be given by a doctor or a nurse". Sustanon is prescription-only wherever it is licensed, testosterone is a controlled drug in the UK, the US and Canada, and people also meet products called Sustanon outside medical care. Those products are not covered by the labels described here, and supraphysiologic (above the natural range) "cycle" doses are not testosterone replacement therapy, or TRT (see TRT vs steroids). [10], [11], [12], [13]

Typical Sustanon 250 Protocols

All three labels give one 250 mg ampoule every 3 weeks. UK and European guidelines keep that interval or stretch it to 4 weeks, while the 2016 Australian position statement shortened it to every 2 weeks. [1], [2], [3], [14], [15], [16], [17]

Titration Adjusting the dose in steps

The labels adjust the dose to the man's response and ask for testosterone to be checked at the start and at regular intervals, without saying when to draw it. If side effects linked to testosterone appear, the UK label says to stop and restart at a lower dose once they settle. With a fixed 250 mg ampoule, guidelines adjust the gap instead. The Society for Endocrinology sets the interval by the trough level at the end of it, aiming for the lower end of normal. The Endocrine Society of Australia also judges injections by the trough. Hematocrit can force a change too. [1], [14], [17] See when blood should be drawn.

Breaks and cycles

Not applicable. Testosterone replacement is continuous treatment; no label or guideline describes planned breaks or cycles, and the UK leaflet warns that the original complaints may return within a few weeks of stopping. Stopping is a separate decision (what happens when you stop). [10]

Read the units. Doses are written in milligrams of the ester mix, not of testosterone. One ampoule is 1 mL, which is 250 mg of the four esters and 176 mg of testosterone itself. Given every 3 weeks, that averages about 83 mg of esters, or about 59 mg of testosterone, a week. For comparison, 100 mg of testosterone cypionate a week, the top of the Endocrine Society's example range (75–100 mg weekly), carries about 70 mg of testosterone. That is arithmetic, not a rule for switching products. The Australian label says an opened ampoule "cannot be resealed" and should be used immediately, so the labels give no smaller volume to measure. Doserly's TRT dose calculator does mg-to-mL arithmetic for any strength. [1], [2], [18], [19]

These are labeled and guideline doses; prescribers adjust them using blood tests and symptoms. The schedules above are for adult men. For women, see testosterone therapy for women, which uses different products and far smaller doses.

Cautions for every schedule above. The labels rule Sustanon out with a peanut or soya allergy, known or suspected prostate or breast cancer, and in pregnancy and breastfeeding. They also rule it out in children under 3 because of its benzyl alcohol, and the Australian label adds a high calcium level in the blood or urine. It shuts down sperm production (fertility), and hematocrit, blood pressure and PSA (prostate-specific antigen, a prostate blood test) need checking (monitoring). [1], [2], [10]

Where sources differ: every 3 weeks vs more often, splitting an ampoule, muscle vs fat and blood-test timing ↓

What do clinic protocol sources use?

This is the only peer-reviewed clinic protocol source found for Sustanon. It starts at a shorter interval than the labels and adjusts toward a target range, but it reports no Sustanon-specific results, so it shows how one service prescribes rather than whether that schedule works better. [24]

What is Sustanon 250 commonly used for?

Its licensed use is replacing testosterone in men with hypogonadism (low testosterone from a medical cause) confirmed by symptoms and blood tests; the UK leaflet asks for two separate blood measurements. The UK label also lists supportive therapy for transgender men, and the New Zealand label adds bone loss caused by low testosterone. These guides are for men. [1], [10], [3], [2]

What does Sustanon improve?

The labels describe what treatment of men with hypogonadism does: testosterone and its products rise, bone density and lean mass increase, body fat falls, and sexual function improves, including libido and erections. The Australian label adds that it has "no data available" from clinical trials of its own. [1], [2]

The small studies of Sustanon itself point the same way. In 24 men whose pituitary sent too little signal, 6 months of Sustanon every 3 weeks brought insulin resistance down to the level of healthy controls and reduced body fat, with no untreated comparison group. In 20 men with low testosterone and type 2 diabetes, Sustanon 200 mg every 2 weeks for 3 months lowered waist size in a placebo-controlled crossover trial. In the larger Testosterone Trials of men 65 and older, a year of gel improved sexual function a little but not energy or walking. [25], [26], [27] See the evidence and the results timeline guide.

How long does Sustanon take to work?

Blood levels peak within 24–48 hours of an injection, but symptoms change more slowly. The Society for Endocrinology says effects on sexual interest, depressive symptoms and energy can appear within 3–6 weeks, while physical changes take longer. [1], [14] See the results timeline guide.

Where do Sustanon 250 protocols differ?

The labels are short and old; the guidelines and practice are more varied. Most real disagreements are about how long to wait between injections, whether the four-ester mix is smoother, whether an ampoule may be split and when to draw blood.

Every 3 weeks or more often?

The labels say every 3 weeks, and UK guidelines accept 3 to 4; shorter gaps come from an Australian statement and private practice. The Society for Endocrinology allows 3–4 weeks and sets the interval by the trough level. The Endocrine Society of Australia used every 2 weeks in 2016, and a UK private provider starts every 2 weeks. A UK paediatric guideline says adult maintenance in practice is mostly every 2–3 weeks. [1], [14], [17], [24], [21]

Doserly

One ampoule, four schedules

The same 250 mg ampoule on each source’s interval over 12 weeks. Each dot is one injection; hollow dots show the 4-week end of a 3–4 week range.

Labels (UK, Australia, NZ)

Every 3 weeks ("usually"): about 83 mg a week on average

Society for Endocrinology 2022

Every 3–4 weeks, set by the trough level: about 63–83 mg a week on average

Endocrine Society of Australia 2016

Every 2 weeks: 125 mg a week on average

UK private-provider cohort 2026Clinic protocol source

Every 2 weeks at the start: 125 mg a week on average

No trial has compared these intervals. BSSM 2023 ('usually every 3 weeks') and EAU 2026 (every 3 weeks) match the label row.

The case for shorter gaps rests on small, old studies of the fall-off before the next injection:

• In 7 men without testicles on Sustanon every 3 weeks, testosterone averaged 35.8 nmol/L (about 1,030 ng/dL) one day after an injection. Just before the next injection it averaged 6.0 nmol/L (about 170 ng/dL), and 6 of the 7 were below 10 nmol/L. Three described irritability, sweating and hot flushes at the end of the interval. [28]
• In men with hypogonadism on these injections, reported sexual function declined when testosterone fell to 5–11 nmol/L, and the author suggested injecting more often. [29]
• Even every 2 weeks, 250 mg of mixed esters caused "marked but reproducible" week-to-week swings in a randomized crossover trial of 15 men. [30]

No randomized trial has compared Sustanon intervals on symptoms or health outcomes. For other injections, the only comparison with clinical results is observational. Hematocrit rose above 54% in 1 of 102 men on 100 mg weekly and 4 of 51 on 200 mg every 2 weeks; the ester was not stated. [31]

Does the four-ester mix give steadier levels?

No study shows it. The idea is that fast and slow esters overlap to smooth the curve, and the European urology guideline says the mixture "has the benefit of a steady release". The same guideline calls these older injections prone to wide swings in testosterone, and the measured studies show a high early peak followed by a long fall. A 2022 review notes that computer simulations suggest ester mixtures swing more than enanthate alone, and that the mixtures have not been studied recently. [16], [32], [28], [33]

What people feel is harder to measure. A 2019 Dutch patient-organisation survey, reported second-hand in a systematic review, found mood swings in 25.3% of Sustanon users, 7.6% of gel users and 5.9% of Nebido users. It was a survey, not a trial, and the review itself contains an error about how often short-acting esters are given. In a Dutch reimbursement review, Nebido's maker argued that its product causes fewer hormone swings than short-acting Sustanon. [34], [35]

Can a Sustanon ampoule be split into smaller, more frequent doses?

The labels describe one whole ampoule per injection, and no guideline gives a split schedule. The Australian label says an opened ampoule "cannot be resealed in such a way to further guarantee the sterility of the contents" and should be used immediately. It describes the vial, which is not available commercially, as "for single use in one patient only". The UK leaflet describes injections given by a doctor or nurse. [2], [10]

Splitting is still common in public forums, where people describe drawing part of an ampoule and storing the rest in syringes for days (what people report). No study has measured whether oil stored that way stays sterile. The weekly total is the number to keep in view: half an ampoule every 10–11 days is still about 83 mg a week. Guidelines and practice sources that shorten the gap do it with whole ampoules given every 2 weeks; changing to another product is the other option a prescriber may weigh. [17], [24]

Intramuscular or subcutaneous?

The labels say intramuscular only. The UK label says oily solutions like Sustanon must be injected "strictly intramuscularly and very slowly", and the UK leaflet gives the buttock, upper leg or upper arm as examples. The Society for Endocrinology names the buttock muscle or upper thigh for short-acting injections. [1], [10], [14]

No study of subcutaneous injection (into the fatty layer under the skin) of Sustanon was found. The subcutaneous evidence comes from other esters: a 2022 review concluded that subcutaneous enanthate or cypionate gives comparable levels but that direct safety comparisons are missing. Whether that transfers to a four-ester mix in peanut oil is unknown. Injection technique is covered in how to inject testosterone. [36]

When should blood be drawn?

On Sustanon, most guidelines that name a time use the trough: blood taken just before the next injection. The labels say only to check testosterone "at regular intervals". The Endocrine Society of Australia warns that "random blood sampling without regard to the timing of the most recent dose is uninformative". A level drawn a day after an injection and one drawn at the end of the interval describe the same dose. [1], [17], [28]

[14], [15], [17], [37], [18]

The UK and Australian documents that give a draw time for Sustanon judge it at the trough. Whatever timing a prescriber uses, writing down the date of the last injection with every result makes results comparable. See TRT blood work for the full picture.

What happens when you stop Sustanon?

The effect fades gradually, and your own hormone production takes longer to return. [10], [1]

• The last injection. The UK leaflet says the effects "do not stop immediately after discontinuation, but gradually subside", and the UK label notes that side effects "cannot be quickly reversed by discontinuing medication". [10], [1]
• Symptoms. The leaflet warns that complaints like those before treatment "may re-occur within a few weeks". [10]
• Your own testosterone. Outside testosterone switches off the pituitary's two signals to the testicles, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In healthy young men given Sustanon for a research study, testicular hormones and LH fell and returned to their starting levels after the suppression ended. In men with a lasting cause of hypogonadism, low testosterone is expected to return, which is why the Society for Endocrinology treats a confirmed diagnosis as lifelong. No study has tracked recovery after years of Sustanon. [38], [14]
• Sperm. In contraceptive trials of healthy men using other testosterone regimens, sperm counts returned to 20 million per mL in 67% within 6 months, 90% within 12 months and 100% within 24 months. [39]
• Tapering. The Canadian Urological Association says no taper is needed when stopping. [40]

See stopping TRT for the full picture, including fertility recovery and what men describe.

How does Sustanon 250 compare with other forms?

It is a short-acting injectable mix of esters. Compared with long-acting undecanoate injections such as Nebido, it is injected far more often; compared with single-ester enanthate, it differs in its ester mix, its oil and its fixed 1 mL ampoule. [1], [41], [42]

Do the four esters really release at different speeds?

The labels say the esters have "different durations of action" and are turned into testosterone "as soon as they enter the general circulation", but they give no timing for each one. No human study measured how each ester behaves inside Sustanon, so the half-life tables for each ester that circulate online have no primary source. What does exist is indirect: [1]

• Propionate alone. In healthy men, 25 mg of a traceable form of testosterone propionate given on its own kept the resulting testosterone above the natural level for 48 hours. [43]
• Decanoate alone. A different decanoate product, given as 400 mg every 4 weeks with a hormonal implant in a contraception study, peaked a week after injection. [44]
• Detection windows. After Sustanon injections, the intact esters stayed detectable in dried blood spots for at least 5 days and up to 14 days for three of them, and detection time depended on the ester. These are detection windows, not half-lives. [45], [46]

The European urology guideline gives the mixture as a whole a half-life of 4–5 days. [16]

What do the peaks and troughs look like?

Measured studies give the shape: a high peak within a day or two, then a long fall. [1]

• Labels. After a single injection, testosterone peaks at about 70 nmol/L (about 2,000 ng/dL) 24–48 hours later and returns to the lower limit of the normal range in about 21 days. [1], [2]
• Men with hypogonadism. In 9 men, mixed esters peaked at a mean of 71 nmol/L at 24–48 hours and fell back to baseline after 2–3 weeks; the average across a 3-week interval was 27.7 nmol/L (about 800 ng/dL). [32]
• Men without testicles. Levels averaged 35.8 nmol/L one day after an injection, with 5 of 7 men above the upper limit of normal, and 6.0 nmol/L just before the next. [28]
• Healthy young men. One injection raised testosterone from 19.8 to 81.4 nmol/L (about 570 to 2,350 ng/dL) at 24 hours. [47]

Doserly

Peaks and troughs after one injection

Days after an injection; ◆ label points, ■ van Basten 1997, dashed line = simplified shape, vertical line = trough draw (day 21).

UK and Australian labels

Peak about 70 nmol/L (about 2,000 ng/dL) 24–48 hours after an injection; back to the lower limit of normal in about 21 days.

Cantrill 1984 (9 men with hypogonadism)

Peak mean 71 nmol/L at 24–48 hours; back to baseline after 2–3 weeks; average 27.7 nmol/L (about 800 ng/dL) over a 3-week interval.

van Basten 1997 (7 men without testicles, every 3 weeks)

35.8 nmol/L (about 1,030 ng/dL) one day after an injection and 6.0 nmol/L (about 170 ng/dL) just before the next; 6 of 7 were below 10 nmol/L at that point.

When blood is drawn

At the trough, just before the next injection (day 21 on the label schedule).

High early, low late: guidelines time the blood test at the trough. The dashed shape is a simplified model fitted to the label, not a prediction for any person.

That shape explains both sides of the interval debate: well above normal early in the interval and near or below the lower limit by the end. One study in young people with thalassaemia, a blood disorder, given a half-strength four-ester mix found a later peak, at 7 days, so the timing can differ by population and dose. [48] Doserly's testosterone level visualizer draws a simplified relative curve for the label schedule and shorter intervals.

Is Sustanon different from cypionate or enanthate?

In practice, three things differ: the ester mix, the oil and where each is sold. Sustanon is a fixed 1 mL ampoule of four esters in peanut oil. Testosterone cypionate is a single ester, in US vials in cottonseed oil, labeled at 50–400 mg every 2–4 weeks; no cypionate product appears in current UK or Australian product information. Enanthate is a single ester sold in the UK as 250 mg/mL ampoules, given every 2–3 weeks at first and then every 3–6 weeks, in castor oil. See the cypionate and enanthate guides. [1], [19], [42], [49], [50]

The practical question is often not the ester but the interval and the dose each product is used at. Posters who switch between them usually change the weekly total or schedule at the same time (community).

What is in the ampoule, and why does peanut oil matter?

Each ampoule holds the four esters in refined arachis (peanut) oil with benzyl alcohol at 100 mg per mL. Because of the oil, the labels make a peanut allergy a contraindication and extend it to soya allergy, "as there is a possible relationship between allergy to peanut and allergy to soya". Because of the benzyl alcohol, it must not be given to babies or children under 3. [1], [2]

The allergy risk from refined oil appears small but is not settled for injections. In a double-blind challenge of 60 people with peanut allergy, none reacted to swallowed refined peanut oil, while 6 (10%) reacted to crude oil, and a smaller older study of 10 found no reactions. A UK paediatric guideline says most people with peanut allergy tolerate the preparation "unless their sensitivity is very high". Those were oral challenges, not injections, and the labels still say not to use Sustanon with a peanut or soya allergy. [51], [52], [21], [1]

Other injections use other oils: US cypionate uses cottonseed oil, US generic enanthate sesame oil, and the UK enanthate ampoules, Australia's Primoteston and Nebido castor oil. A man with a peanut allergy has other options to discuss with his prescriber. [19], [53], [42], [54], [41]

How should Sustanon be stored?

Store it at room temperature, away from light and out of the fridge. Each label sets its own rules, so the leaflet in your box is the final word. [1], [2]

[1], [2]

For carrying ampoules on a trip, see traveling with testosterone. This guide does not teach injection technique; the Academy note below covers the practical basics, and how to inject testosterone covers sites and needles.

What does Sustanon 250 do to fertility, estrogen and red blood cells?

These three effects come with every form of testosterone; each has its own hub guide. Here is what is specific to Sustanon.

Fertility. The UK label says androgens "can lead to fertility disorders by repressing sperm-formation", and the British Society for Sexual Medicine says testosterone therapy typically suppresses sperm production within 3–6 months. In healthy young men, Sustanon injections switched off LH and the testicles' own hormones until the suppression ended. The US urology guideline says testosterone should not be prescribed to men trying to conceive. See TRT and fertility. [1], [55], [38], [56]

Estrogen. Some testosterone is converted into estradiol. After a mixed-ester injection, estradiol rose above the normal male range at 24–48 hours, to a mean of 347 pmol/L (about 95 pg/mL), tracking the testosterone peak. In men without testicles, it was more than twice as high a day after the injection as at the end of the interval. No guideline sets a routine estradiol target: the US urology guideline measures it mainly when breast symptoms appear. See estrogen on TRT. [32], [28], [56]

Red blood cells. The UK label lists rises in hematocrit, red cells and hemoglobin as common. In a UK hospital clinic, polycythemia (a hematocrit above 0.505 or hemoglobin above 17 g/dL) developed in 5 of 30 men on Sustanon (17%), 12 of 86 on Nebido (14%) and 8 of 57 on gel (14%). The difference was not significant, and the report was a conference abstract without dose data. Across 29 randomized trials of all forms, enanthate or cypionate injections raised hematocrit about 4.0 percentage points more than placebo. UK and Australian labels also warn that SGLT-2 inhibitors, a class of diabetes medicines, can add to the rise. See hematocrit on TRT. [1], [57], [58], [2]

What do we actually know about Sustanon in people?

That it restores testosterone is settled; it has been licensed in the UK since 1973. What it does over years comes mostly from trials of other forms of testosterone. The Australian label says there are "no data available" from clinical trials of its own, and the studies of Sustanon itself are small, short or decades old. [1], [2]

Which studies used Sustanon or mixed esters?

Two small reports from UK and Czech clinics describe satisfaction in 9 of 10 men on Sustanon and symptom-free prostate cysts or calcium deposits on scans in long-term users; neither had a comparison group. [61], [62]

What did the large trials of other forms find?

• TRAVERSE (about 5,200 men, daily gel): heart attack, stroke or heart death in 7.0% vs 7.3% on placebo (hazard ratio 0.96), which met the trial's safety margin, but more heart-rhythm, kidney, clot and fracture events. It tested only a gel, men used it for 21.7 months on average, and about 61% stopped early (full results). [63], [64]
• Testosterone Trials (790 men aged 65 or older, gel for 1 year): small gains in sexual function; no gain in energy or walking. [27]

Whether those results transfer to a short-acting injection with high peaks is not known. [63]

How does Sustanon 250 work?

Once injected, the oil forms a depot in the muscle. The esters move out of the oil into the blood, where enzymes remove their tails and free testosterone; the UK label says this happens "as soon as they enter the general circulation". [1] Testosterone injected without an ester lasts only minutes; the ester lets it dissolve in the oil and leave slowly, which is why one injection lasts weeks. [33]

Testosterone then acts like the body's own hormone. It is converted to dihydrotestosterone (DHT) and estradiol, and over 97% of it in the blood is bound to proteins, including sex hormone-binding globulin (SHBG). [1]

Why it switches off your own production. The brain senses testosterone from any source. When levels are high, the pituitary lowers its LH and FSH signals, so healthy testicles make less testosterone and sperm. The labels say that in men with hypogonadism, treatment brings LH and FSH "to the normal range"; in men whose own signals were normal, as in the healthy volunteers above, outside testosterone pushes them down. [1], [38]

Why it raises red blood cells. Androgens stimulate red blood cell production; the UK label lists the rise in hematocrit among the common effects and notes it "may lead to polycythaemia". [1]

What are the risks and unanswered questions?

Is Sustanon safe?

For men with a confirmed diagnosis and regular monitoring, it has more than 50 years of licensed use. Its main risks are well known: a rise in red blood cells, blood clots, higher blood pressure, fluid retention, breast enlargement, prostate effects and loss of fertility. Less certain is long-term heart and prostate safety on high-peak injections, since the largest safety trial used a gel. The effect of repeated peanut-oil injections in people with a peanut allergy is also unknown. [1], [63]

What side effects do the labels list?

The UK label lists weight gain and rises in hematocrit, red cells and hemoglobin as common. Other effects are listed with frequency not known. Skin and body effects include acne, itching, fluid retention, high blood pressure, nausea, muscle pain and breast enlargement (gynecomastia). Mood effects include depression, nervousness and mood changes. Sexual and prostate effects include changes in sex drive, prolonged erections, ejaculation problems, a low sperm count, prostate growth and a rise in PSA. Liver tests and cholesterol can also change. The Australian label also lists dizziness, headache, flushing, abdominal pain and urination problems, and calls injection-site reactions common. [1], [2]

What is "Sustanon flu"?

It is a forum term, not a medical one. The Australian label lists "fever, malaise" as rare effects of androgen therapy and local injection-site reactions as common. No study has examined a flu-like reaction after Sustanon or explained one. [2] The UK leaflet asks you to tell your doctor, pharmacist or nurse about any side effect, including ones it does not list, so fever, chills or aches after an injection are worth reporting rather than waiting out. [10] See what people report.

Can an oil injection cause a cough?

Rarely. Oil injected into muscle can reach the lungs as tiny droplets (pulmonary oil microembolism). The UK label lists it as rare, with cough, shortness of breath, feeling unwell, sweating, chest pain, dizziness, pins and needles or fainting "during or immediately after the injection". The reactions are reversible, and the label says the patient should be observed during and just after each injection. In September 2025 the EU safety committee recommended adding this warning for all oil injections of testosterone. In an older study of 551 weekly enanthate injections in castor oil, 1.5% were followed by a brief cough with faintness; no incidence figure exists for Sustanon itself. [1], [65], [66]

Does Sustanon affect the heart?

The best evidence comes from TRAVERSE, a randomized trial of about 5,200 men aged 45 to 80 with heart disease or high heart risk, given daily testosterone gel or a placebo gel. Among the 2,596 men who used testosterone gel and the 2,602 who used placebo gel, it found:

• Heart attack, stroke or heart death: 182 men (7.0%) on testosterone vs 190 (7.3%) on placebo; hazard ratio 0.96, with a 95% confidence interval of 0.78 to 1.17. The top of that range stayed below the trial's safety margin of 1.5, so a large rise in risk was ruled out. [63]
• Heart rhythm: atrial fibrillation 3.5% vs 2.4%; nonfatal rhythm problems needing treatment 5.2% vs 3.3%. [64]
• Kidneys: acute kidney injury 2.3% vs 1.5%. [64]
• Clots: venous clots 1.7% vs 1.2%, including pulmonary embolism 0.9% vs 0.5%. [64]
• Fractures: 91 of 2,601 men (3.50%) vs 64 of 2,603 (2.46%), counting every randomized man. [67]
• Blood pressure: systolic pressure rose 1.0 mm Hg on testosterone and fell 0.5 mm Hg on placebo by 36 months. [64]
• Substudies: in men with low libido, testosterone increased sexual activity and desire but not erections; it did not significantly slow progression from prediabetes to diabetes; and it did not improve persistent depressive disorder in the 49 men who had it. [68], [69], [70]

Doserly

TRAVERSE: absolute results

Testosterone gel (2,596 men)Placebo gel (2,602 men)

Heart attack, stroke or heart death

Testosterone 7.0% vs placebo 7.3% (182 vs 190 men; hazard ratio 0.96, 95% CI 0.78–1.17; met the 1.5 safety margin)

Nonfatal rhythm problems needing treatment

Testosterone 5.2% vs placebo 3.3%

Atrial fibrillation

Testosterone 3.5% vs placebo 2.4%

Clinical fracture

Testosterone 3.5% vs placebo 2.5% (91 of 2,601 vs 64 of 2,603 in the full analysis set)

Acute kidney injury

Testosterone 2.3% vs placebo 1.5%

Venous clots (all)

Testosterone 1.7% vs placebo 1.2%

Pulmonary embolism

Testosterone 0.9% vs placebo 0.5%

About 5,200 men aged 45–80 at high heart risk; daily gel; mean treatment 21.7 months; about 61% stopped their study gel. Not a trial of injections.

Its limits matter for Sustanon. TRAVERSE tested only a gel, the average man used it for 21.7 months, about 61% stopped their study gel early, and it enrolled men at high heart risk. It did not test the high peaks of a 3-weekly injection. A 2025 meta-analysis of 23 trials lasting at least a year found no increase in death, heart attack or stroke, but about 50% more heart-rhythm problems in relative terms (risk ratio 1.53); the abstract gives no absolute rates. [63], [71]

What the Sustanon labels say. The UK and Australian labels do not mention TRAVERSE. They warn about fluid build-up with or without heart failure in men with serious heart, liver or kidney disease. They ask for monitoring after a heart attack or with high blood pressure, and say testosterone "may cause a rise in blood pressure". The US label changes of 2025 and the label changes requested in June 2026 do not apply, because Sustanon has no US label. [1], [2], [72], [73]

See TRT and heart health for the full picture.

What about blood clots, sleep apnea and fluid retention?

• Blood clots. The labels report clots in the legs, lungs and eyes in men with thrombophilia (a tendency to clot) or other clot risk factors, in some cases even on blood thinners. Painful swelling of one leg, sudden breathlessness, coughing up blood or sudden chest pain need urgent assessment. [1], [10]
• Sleep apnea. The UK label says there have been reports that testosterone can cause or worsen sleep apnea, with extra caution in men with obesity or chronic lung disease. [1]
• Fluid retention. Swelling, with or without heart failure, can be serious in men with heart, kidney or liver disease; the UK label also asks for monitoring in epilepsy and migraine. [1]

Could Sustanon affect the prostate?

Testosterone can enlarge the prostate and raise PSA slightly; in TRAVERSE, PSA rose about 0.15 ng/mL more than on placebo at 12 months. The Sustanon labels contraindicate it in known or suspected prostate cancer. They advise prescribers to consider a rectal examination and PSA before starting, every 3 months in the first year and then yearly. TRAVERSE excluded men with PSA above 3.0 ng/mL; in it, high-grade prostate cancer occurred in 5 of 2,596 men on testosterone (0.19%) vs 3 of 2,602 on placebo (0.12%), a difference that was not significant. [74], [1] See TRT and the prostate.

Is Sustanon legal? Is it FDA approved?

Checked September 2026. Rules differ by country and change often.

United Kingdom. Sustanon 250 has current UK product information and is prescription-only. Testosterone is a Class C controlled drug (Schedule 4 Part II). Possessing it is not an offence, and carrying your own supply in person is exempt from import rules, but supplying it without authority is an offence. [1], [11], [75]

Australia. The ampoule is registered; the vial and 3-ampoule packs are not available commercially. Testosterone is a Schedule 4 (prescription-only) medicine with extra controls on possession. Sustanon has no listing on the Pharmaceutical Benefits Scheme (PBS), which subsidizes medicines, in the September 2026 schedule; the mixed-esters injection was delisted in January 2012 and can still be prescribed privately. [2], [76], [77]

New Zealand. Sustanon 250 is a Prescription Medicine, supplied as ampoules. Pharmac lists Sustanon Ampoules as the fully subsidised brand of this injection, with a subsidy of NZ$12.98 per ampoule; that is a subsidy amount, not a retail price. [3], [78]

Europe. Rules are national. The Netherlands (since 1963) and Belgium authorise Sustanon on prescription. Italy lists it as a patient-pays product on a restricted specialist prescription and authorised imports during a 2019 shortage. Ireland's licence was withdrawn on December 4, 2008, and no current Irish authorisation was found. Other countries were not checked for this guide. [4], [5], [6], [79], [80], [7] See TRT in Europe.

United States. Sustanon is not FDA-approved: there is no FDA application and no US label for it or for three of its four esters. Testosterone and its esters are Schedule III controlled substances, so any product sold in the US as Sustanon is not an approved medicine. [8], [12]

Canada. There is no Sustanon product in Health Canada's database, and no product containing its decanoate, isocaproate or phenylpropionate esters. Testosterone is a Schedule IV controlled substance. [9], [13]

A "research use only" label on a vial does not make it legal, tested or the same as a licensed product.

Is Sustanon banned in sport? Does it show up on a drug test?

Checked September 2026.

Yes. Testosterone and its esters are on the World Anti-Doping Agency (WADA) Prohibited List in class S1, banned in and out of competition, and the 2027 list keeps that from January 1, 2027. The Sustanon labels warn that it "can interfere with anti-doping testing". Athletes with a medical need can apply for a therapeutic use exemption. WADA grants one only when low testosterone has an organic cause (such as a testicular or pituitary disorder), not for age, obesity or earlier steroid use. Its exemption guidance groups mixed esters with enanthate and cypionate. [81], [82], [1], [20]

Anti-doping research shows why. After Sustanon injections, the intact esters stayed detectable in dried blood spots for at least 5 days, and up to 14 days for three of them. In 9 healthy men given two injections 3 weeks apart, the athlete passport's steroid section flagged all 9 as suspicious and its blood-cell section flagged 6. No source gives a fixed clearance time. [45], [83]

Who should be especially cautious?

• People with a peanut or soya allergy. Contraindicated on every label. [1]
• Men who want children now or soon. Testosterone suppresses sperm production, and recovery can take months or longer. [56], [39]
• Men with prostate or breast cancer, or high calcium. Contraindicated (the calcium rule is on the Australian label). [1], [2]
• Heart, kidney or liver disease, high blood pressure, epilepsy or migraine. Fluid retention and blood-pressure rises can worsen these, and the labels ask for monitoring. [1]
• A history of clots or thrombophilia. Clots have been reported even on blood thinners. [1]
• Sleep apnea. A caution on the labels. [1]
• Men over 65. The UK label notes "limited experience" in this age group. [1]
• Women and children. Contraindicated in pregnancy and breastfeeding, and never for children under 3; use in teenagers is specialist care only, because androgens can close growth plates early. These guides are for men. [1], [21]
• Drug-tested athletes. Banned at all times. [81]
• People taking other medicines, such as blood thinners, diabetes medicines or corticosteroids; see the next question.

Can Sustanon be taken with other medicines?

The labels list these interactions:

• Blood thinners of the coumarin type (such as warfarin). Androgens can strengthen their effect, so prothrombin time (a clotting test) needs close monitoring and the blood thinner dose may need lowering. [1]
• Insulin and other diabetes medicines. Testosterone can improve glucose tolerance and lower the need for them, especially at the start and end of treatment. [1]
• SGLT-2 inhibitors (such as empagliflozin or dapagliflozin). Together they can raise hematocrit more; the labels advise checking hematocrit and hemoglobin. [1], [10]
• ACTH or corticosteroids. Together they can increase fluid retention. [1]
• Medicines that speed up or slow down liver enzymes (such as the epilepsy medicine phenobarbital). They can lower or raise testosterone levels. [1], [10]
• Cyclosporin (ciclosporin). The Australian label says androgens may increase its effects and the risk of kidney damage. [2]

Testosterone can also lower thyroxine-binding globulin, which changes total thyroid hormone results without changing thyroid function. Bring a full list of everything you take, including supplements, to a pharmacist or doctor. [1]

Is Sustanon available, and what does it cost?

Checked September 2026.

It is sold as a box of one ampoule in the UK and as single ampoules in Australia and New Zealand. In New Zealand the public subsidy is NZ$12.98 per ampoule. No current UK or Australian price was verified for this guide, and in Australia it is prescribed privately because it has no PBS listing. No UK shortage notice was verified for this guide; Italy had a national shortage in 2019. [1], [2], [78], [77], [80]

What should be monitored while using Sustanon?

The labels ask for testosterone at the start and at regular intervals. They advise prescribers to consider a rectal prostate examination, PSA, hematocrit and hemoglobin before starting, every 3 months for the first 12 months and yearly after that. The UK label adds liver tests and cholesterol for long-term use. They give no numeric hematocrit limit. The numbers come from guidelines. Use this summary to prepare questions for your prescriber; it is not a personal testing plan. [1], [2]

[1], [14], [17], [18], [56], [16], [15], [37], [84], [85], [40]

Doserly

Where guidelines draw the hematocrit line on TRT

On-treatment hematocrit (%) at which each body acts.

Each bar runs from 46% (left) to 56% (right); the shaded part is 48–50%, where most guidelines take care before starting.

Society for Endocrinology (UK, 2022)

Above 50% (0.50 L/L)

VA (US, January 2026)

Above 51%: adjust the dose · above 54%: stop

AUA (US, 2018, reconfirmed 2024)

54% or higher

Endocrine Society (2018)

Above 54%

EAU (Europe, 2026)

Above 54% (summary table: 54% or higher)

BSSM (UK, 2023)

Above 54%

ICSM (2024)

Keep below 54%

EAA (Europe, 2020)

Above 54%

CUA (Canada, 2021)

55% or higher, if it persists

Product labels (US, UK, Canada)

No number: labels say “elevated”

No trial has tested which line prevents clots or heart events.

The shaded 48–50% band is a starting check: the Endocrine Society, EAU, ICSM and EAA ask for care or further evaluation before starting testosterone when hematocrit is already in that range. [18], [16], [37], [84]

The Society for Endocrinology's line, 0.50, is lower than most; its options include lengthening the injection interval or switching to a gel. See TRT blood work and hematocrit on TRT. [14]

Write down the timing. For every testosterone or hematocrit result, note the date of the last injection. On a 3-week interval, a result without its timing is hard to interpret. [17]

What do people in public communities report?

Public forums hold every kind of Sustanon story: men who feel well on it for years, men who feel it fade before the next injection, and men who stopped after side effects. The accounts below come from public Reddit threads from the past year and are described without identifying anyone. Many posters are in the UK, where Sustanon is prescribed.

What do the positive reports look like?

Steadier energy, clearer thinking and better sex drive are the usual good news. A UK man who had used prescribed Sustanon, 125 mg a week, for several years said he felt reasonably well on it and did not want to change. When his pharmacy warned of a shortage, it found stock the next day. A UK man in his 40s two months into treatment, on 175 mg a week, described less brain fog and better energy and recovery, though his libido had not yet returned and his estrogen result had risen. [86], [87]

Early effects do not always last. A man in his 40s on 125 mg a week, in two injections, described a sharp rise in libido when he started. After about a year it had settled back close to its earlier level, while he still felt well overall. A man in his 30s on 175 mg a week, injected every 3 days, felt much more energetic and motivated at 3 months but also noticed occasional nipple sensitivity. [88], [89]

Does everyone respond?

No. A man in his 30s on 250 mg every 21 days for 14 weeks felt little benefit. His testosterone just before the next injection was 284, close to his starting 264 (units not given), and his libido tended to fall after day 15. His doctor would not raise the dose because his hematocrit had reached 51%. Another man, on 120 mg a week in two injections, had a higher testosterone reading after 8 weeks but felt no better and noticed scalp acne; he was also sleeping about 6 hours a night. A third, on 125 mg weekly, felt no change after four weeks despite a reading of 15.2 nmol/L the day before an injection. [90], [91], [92]

What do people say about the 3-week interval?

It is the most discussed topic, and most replies distrust long gaps:

• Worn off before the next dose. A man on 250 mg once a month felt better in weeks 1 and 2 and back toward his starting point in weeks 3 and 4, two months in a row. A UK man given injections every 12 weeks (dose not stated), and later 250 mg monthly, described a good first month after each one before his mood, skin and pain symptoms returned. [93], [94]
• Low readings at the end of long intervals. A UK man in his 50s with secondary hypogonadism on 250 mg every 4 weeks had a reading of 4.6 nmol/L three weeks after an injection; his clinician shortened the interval to 3 weeks. A later post described swelling and muscle pain, and he stopped Sustanon for another product. [95], [96]
• Swings at 3 weeks too. A man in his 30s on 250 mg every 21 days for 9 months described peaks "in the 1500s" and troughs under 300 (units not stated). He also described estrogen spikes and a hematocrit of 55% that needed blood removal. [97]
• Shorter intervals helped one man but raised his red cells. A man in his 40s who moved from Nebido found monthly Sustanon left his testosterone at about 100 ng/dL. Injections every 15 days, and then half an ampoule about weekly, felt much better. But his hematocrit reached 52.1% and stayed high, and his doctor asked him to go back to monthly. [98]

Men newly prescribed the label schedule often ask whether to split the ampoule before they have tried it; replies disagree, and several point to the prescriber as the person to ask. [99]

Do people split the ampoule?

Many do, and the threads show why the label's single-use wording matters. Posters describe splitting one ampoule into two 125 mg injections and storing the second in a capped syringe for several days, or planning ten daily 0.1 mL doses from one ampoule. Replies debate sterility, filter needles and syringe materials; one commenter who had used three portions per ampoule for years reported no infections but had seen rubber plungers swell in cheaper syringes. None of these threads measured whether stored syringes stay sterile. One UK man said his clinic would not allow split doses at all. [100], [101], [102], [103]

More frequent injections did not settle everyone. A man injecting 0.3 mL every 2 days to avoid dips reported severe mood swings after 15 days, and replies thought his weekly amount was too high. Another on twice-weekly subcutaneous injections felt swollen until he lowered his weekly amount, and was then puzzled when a second trough test showed lower testosterone but higher estradiol. [104], [105]

What unwanted effects come up?

• Injection pain and lumps. A man on 0.5 mL every 5 days described painful swelling after injections into muscle. Another, ten weeks in (dose not stated), believed a nurse had given one injection subcutaneously, into the fatty layer rather than the muscle, by mistake and described a burning leg. [106], [107]
• Acne. A man in Ireland described severe back acne on prescribed Sustanon; smaller injections of 0.17 mL every other day helped only somewhat. [108]
• Red blood cells. A man on 125 mg a week who felt well had a hematocrit of 0.52 on blood drawn 24 hours after an injection, down from 0.54 earlier. [109]
• Sleep apnea. After nearly two years (dose not stated), one man stopped injections because of worsening sleep apnea, a thicker neck and irritability; weeks later he reported that the apnea had resolved but he had lost muscle. [110]
• Heart rhythm and blood pressure. After about 10 years on Sustanon (dose not stated), one man with palpitations after injections tried weekly enanthate during a supply gap and found the palpitations milder. Another, switched from enanthate to Sustanon because of supply problems (dose not stated), went to hospital with tunnel vision, a racing heart and very high blood pressure. The dizziness stopped about 10 days after he switched back, and two heart tests were normal. [111], [112]
• Anxiety. A man in his 20s whose anxiety had been controlled on enanthate developed severe physical anxiety during a two-week switch to Sustanon at the same dose (amount not stated), injected every 3 days, and was still recovering seven weeks later. [113]

The "Sustanon flu" some posters mention was described by one man as body aches, chills and a sore throat after large injections taken alongside another steroid; commenters suspected an ordinary infection. [114] See what the labels say.

What happens when people switch between Sustanon and a single ester?

Experiences point both ways, and the dose or schedule usually changed too:

• One man who switched to cypionate after three months of swings, anxiety and nipple tenderness felt calmer but more tired; his weekly dose was also lower. [115]
• Another planned to return to Sustanon because he had felt more focused on it than on cypionate (62.5 mg every 3 days), although he sometimes injected cypionate late. [116]
• A man who moved from Sustanon to enanthate at the same dose (amount not stated), because of water retention, felt low and less interested in sex in the first days. [117]

Is it always Sustanon 250?

No. Many threads describe products called "Sustanon 300", "350" or "500" bought outside pharmacies, with different strengths and ester mixes from the licensed product. Posters describe painful injections with a 500 mg/mL blend, and one self-directed course of a 300 mg/mL blend ended with skipped heartbeats and a hematocrit of 57.9%. These are not the product described by the labels in this guide. Many other threads describe non-prescribed "cycles" at several times replacement doses, which are outside testosterone replacement therapy and this guide (TRT vs steroids). [118], [119]

How can you judge a Sustanon story?

Ask: Was it prescribed Sustanon 250, or another blend? Was a whole ampoule injected, and how often? What was the weekly total in mg? Was it injected into muscle or subcutaneously? When was blood drawn relative to the last injection? What else changed at the same time, such as hCG, an aromatase inhibitor, other steroids, weight loss or sleep? What happened a few months later?

These selected discussions show what people experience and the questions research should answer. They are not a survey of all users, a success rate or a substitute for the studies.

How does Sustanon 250 compare with other testosterone forms?

These are the forms most often weighed against Sustanon in the countries where it is sold. Status was checked in September 2026.

No trial ranks these forms on long-term outcomes. The practical differences are how often you dose, how much levels swing, how much hematocrit rises and whether someone else can be exposed. See also testosterone propionate, one of Sustanon's four esters sold on its own in some countries, and cypionate vs enanthate.

Common questions about Sustanon 250

What is the usual dose of Sustanon 250?

The UK, Australian and New Zealand labels give one 250 mg (1 mL) injection every 3 weeks. UK guidelines use every 3 to 4 weeks, and the 2016 Australian position statement used every 2 weeks. The prescriber adjusts it, usually by changing the interval, using trough blood tests and symptoms. [1], [14], [17] See typical protocols.

Why is Sustanon given every 3 weeks when levels drop before then?

The 3-week interval comes from the label, which says one injection every 3 weeks is "usually" adequate. Studies show testosterone well above normal early in the interval and near or below the lower limit by the end, and some men notice symptoms returning in the last week. Guidelines handle this by checking the trough and adjusting the interval, from 2 to 4 weeks depending on the source. [1], [28], [14], [17] See every 3 weeks or more often.

Can I split a Sustanon ampoule?

The labels describe one whole ampoule per injection, and the Australian label says an opened ampoule cannot be resealed and should be used immediately. No guideline gives a split schedule, and no study has checked the sterility of oil stored in syringes. Ask your prescriber about a shorter interval or another product instead. [2] See splitting an ampoule.

I have a peanut allergy. Can I use Sustanon?

No. The labels contraindicate it with a peanut or soya allergy because it is made with refined peanut oil. Oral challenge studies suggest refined oil rarely causes reactions, but they did not test injections. Other injections use cottonseed, sesame or castor oil, so ask your prescriber about alternatives. [1], [51] See peanut oil.

Is Sustanon available in the United States or Canada?

No. There is no FDA approval or US label for Sustanon, and no Sustanon product in Health Canada's database. Any product sold as Sustanon in either country is not an approved medicine there. [8], [9] See legal status.

Is Sustanon better than cypionate or enanthate?

No trial has compared them head to head on symptoms or safety. Sustanon's four esters have not been shown to give steadier levels; the main differences are the oil, the fixed ampoule and where each is sold. [33], [1] See how it compares.

Why do I cough right after the injection?

A sudden cough or breathlessness during or just after an oil injection can be a rare reaction to tiny oil droplets reaching the lungs. The labels say it passes and that people should be observed during and just after each injection; tell whoever gives the injection straight away. [1] See oil in the lungs.

What should I do if I miss an injection?

The UK leaflet says to talk to your doctor or nurse as soon as possible and not to inject a double dose to make up for it. If a blood test is due, tell the prescriber when your last injection actually was. [10]

Glossary

Plain explanations of the medical, dosing and research terms used in this guide. Underlined terms in the text link here.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Ampoule

A small sealed glass container holding one dose. Once opened it cannot be resealed, so it is meant to be used at once. Sustanon 250 comes in 1 mL ampoules.

Arachis oil

Peanut oil. Sustanon 250 is dissolved in refined arachis oil, which is why the labels rule it out for people with a peanut or soya allergy.

Aromatase inhibitor

A medicine, such as anastrozole, that blocks the enzyme that turns testosterone into estradiol. It is not routinely used with testosterone therapy.

Azoospermia

No sperm at all in a semen sample.

Controlled substance

A medicine whose prescribing and possession are restricted by law because it can be misused. Testosterone is Class C in the UK, Schedule 4 in Australia, Schedule III in the US and Schedule IV in Canada.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

Depot

A pool of medicine left in the body, such as oil in a muscle, that releases the drug slowly over days or weeks.

Dose (amount each time)

The amount given on one occasion. A protocol lists both the dose and how often it is given.

Ester

A chemical tail joined to testosterone that makes it dissolve in oil and release slowly after injection. The body removes the tail to free testosterone. Sustanon contains four: propionate, phenylpropionate, isocaproate and decanoate.

Estradiol

The main form of estrogen. In men it is made mostly from testosterone, so it rises when testosterone rises.

Eugonadal

Having testosterone in the normal range. Labels ask prescribers to keep men on treatment eugonadal.

FSH (follicle-stimulating hormone)

A pituitary hormone that acts on the cells supporting sperm production. Testosterone therapy lowers it.

Gynecomastia

Growth of breast tissue in men, often tender at first. It is linked to a higher estrogen-to-testosterone balance.

Half-life

The time it takes for the level of a substance in the blood to fall by half. For injected esters it mostly reflects slow release from the oil depot. It is not the same as how long an effect lasts.

Hematocrit

The share of the blood made up of red blood cells, written as a percentage or a fraction (0.50 is 50%). Testosterone raises it, and most guidelines act when it reaches about 54%.

Hypogonadotropic hypogonadism

Low testosterone because the brain and pituitary send too little LH and FSH to the testicles. Also called secondary hypogonadism.

Hypogonadism

Low testosterone caused by a problem in the testicles or in the brain and pituitary signals that control them, confirmed with symptoms and repeated morning blood tests.

Intramuscular (IM)

Injected into a muscle. The Sustanon labels specify deep intramuscular injection only.

LH (luteinizing hormone)

A pituitary hormone that tells the testicles to make testosterone. Testosterone therapy switches it off.

MACE (major adverse cardiovascular events)

A combined measure used in heart-safety trials. In TRAVERSE it meant heart attack, stroke or death from heart disease.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Polycythemia (erythrocytosis)

Too many red blood cells, shown by a high hematocrit. Testosterone therapy is a common cause.

Pulmonary oil microembolism (POME)

Tiny droplets of injected oil reaching the lungs, causing a sudden cough or shortness of breath during or soon after an injection. It is rare and passes.

Primary hypogonadism

Low testosterone because the testicles themselves do not work well, even though the pituitary sends plenty of LH and FSH.

PSA (prostate-specific antigen)

A blood test for a protein made by the prostate. It rises slightly on testosterone and is used to decide whether prostate checks are needed.

SHBG (sex hormone-binding globulin)

A blood protein that carries testosterone. Testosterone bound to it is not immediately available to tissues, so SHBG affects how much free testosterone there is.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. It is not a route on the Sustanon labels, and no study has tested it for Sustanon.

Titration

Adjusting a dose or interval in steps, usually based on blood tests and symptoms.

Trough level

The lowest level of a drug in the blood, measured just before the next dose. UK and Australian guidelines judge Sustanon by it.

TRT (testosterone replacement therapy)

Prescribed testosterone, by injection, gel or other forms, for men with low testosterone. It switches off the brain's LH and FSH signals.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport. Testosterone is banned at all times.

Weekly total

All the amounts given in one week, added together. For example, 250 mg every 3 weeks averages about 83 mg a week.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it. They include product labels and leaflets from the United Kingdom, Australia, New Zealand and Belgium, and clinical guidelines from the United Kingdom, Europe, Australia, the United States and Canada. They also include published clinical trials and studies, regulator databases and legislation. We also reviewed public online forums where people describe their own experiences with Sustanon.

The guide cites 120 sources, including 12 product labels and leaflets, 12 guidelines and position statements, and 33 original studies in people, plus 34 public community threads. Each type of source answers a different question. Labels, guidelines and trials show what was approved and measured. Practice papers show how prescribers typically use it. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources